Limosilactobacillus is a genus of Gram‑positive, facultatively anaerobic bacteria belonging to the family Lactobacillaceae within the order Lactobacillales. The genus was erected in 2020 following a taxonomic overhaul of the large and heterogeneous genus Lactobacillus, which was split into multiple novel genera based on whole‑genome phylogenetic analyses, average nucleotide identity, and phenotypic characteristics.
Taxonomic Position
- Domain: Bacteria
- Phylum: Firmicutes
- Class: Bacilli
- Order: Lactobacillales
- Family: Lactobacillaceae
- Genus: Limosilactobacillus (authority: Zheng et al., 2020)
Defining Features
- Cells are rod‑shaped and can occur singly or in short chains.
- They are catalase‑negative and produce lactic acid as the main metabolic end‑product of carbohydrate fermentation.
- The genus is distinguished from other lactobacilli by specific phylogenomic markers and by a tendency toward slower growth on common laboratory media.
- Many species are tolerant of low pH and can survive in fermentative environments.
Representative Species
| Species | Notable Characteristics / Habitat |
|---|---|
| Limosilactobacillus fermentum | Isolated from human intestinal tracts, fermented foods, and clinical samples; known for probiotic potential and production of exopolysaccharides. |
| Limosilactobacillus reuteri | Formerly Lactobacillus reuteri; commonly found in the gastrointestinal tract of humans and many animals; produces reuterin, a broad‑spectrum antimicrobial compound. |
| Limosilactobacillus rhamnosus | Widely studied probiotic strain (formerly Lactobacillus rhamnosus GG); used in dietary supplements and functional foods. |
| Limosilactobacillus mucosae | Isolated from mucosal surfaces; associated with mucin degradation. |
| Limosilactobacillus salivarius | Commonly found in the oral cavity and gut; explored for oral health applications. |
Ecology and Applications
Members of Limosilactobacillus are frequently isolated from fermented foods (e.g., dairy, vegetable fermentations), animal gastrointestinal tracts, and environmental samples rich in carbohydrates. Several species are employed as probiotics due to their ability to modulate host immune responses, competitively inhibit pathogenic microbes, and enhance barrier function of the intestinal epithelium. The production of antimicrobial metabolites such as reuterin and bacteriocins contributes to their utility in food preservation and health‑related research.
Genomic Insights
Whole‑genome sequencing of Limosilactobacillus species reveals a relatively small genome size (≈1.7–2.3 Mb) with a high proportion of genes involved in carbohydrate transport and metabolism, stress response, and adhesion. Comparative genomics supports the separation of Limosilactobacillus from the former Lactobacillus clade, reflecting distinct evolutionary lineages.
Regulatory and Clinical Status
Some strains (e.g., L. rhamnosus GG) have attained “Generally Recognized As Safe” (GRAS) status in the United States and are approved for use in food and dietary supplement formulations. Clinical investigations have examined their efficacy in preventing or alleviating gastrointestinal disorders, respiratory infections, and atopic dermatitis, although outcomes vary and depend on strain‑specific properties.
References
- Zheng, J., et al. (2020). “A taxonomic note on the genus Lactobacillus: description of 23 novel genera, emended description of the genus Lactobacillus and the union of Lactobacillaceae and Leuconostocaceae.” International Journal of Systematic and Evolutionary Microbiology, 70(4), 2782‑2858.
- Duar, R., et al. (2021). “Probiotic potential of Limosilactobacillus spp.: a review.” Frontiers in Microbiology, 12, 758349.
- OECD (2022). “Safety assessment of probiotic microorganisms.” Food Safety.
Note: The information presented reflects the current scientific consensus up to 2024‑06 and relies on peer‑reviewed literature and recognized taxonomic databases.
